• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Alaunos Therapeutics Inc.

    5/21/25 8:45:49 AM ET
    $TCRT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TCRT alert in real time by email
    DEFA14A 1 d921291ddefa14a.htm DEFA14A DEFA14A

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

     

    SCHEDULE 14A

    (Rule 14a-101)

    INFORMATION REQUIRED IN PROXY STATEMENT

    SCHEDULE 14A INFORMATION

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

     

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) 

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material Pursuant to § 240.14a-12

    Alaunos Therapeutics, Inc.

    (Name of Registrant as Specified in Its Charter)

    (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

    Payment of Filing Fee (Check the appropriate box):

     

    ☒

    No fee required.

     

    ☐

    Fee paid previously with preliminary materials.

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.


    LOGO

    Your Vote Counts! ALAUNOS THERAPEUTICS, INC. 2025 Annual Meeting Vote by July 2, 2025 11:59 PM ET ALAUNOS THERAPEUTICS, INC. ATTN: SECRETARY 2617 BISSONNET, SUITE 225 HOUSTON, TX 77005 V75375-P34532 You invested in ALAUNOS THERAPEUTICS, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on July 3, 2025. Get informed before you vote View the Notice and Proxy Statement and Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to June 19, 2025. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit www.ProxyVote.com Control # Smartphone users Vote Virtually at the Meeting* Point your camera here and July 3, 2025 9:00 AM EDT vote without entering a control number Virtually at: www.virtualshareholdermeeting.com/TCRT2025 *Please check the meeting materials for any special requirements for meeting attendance.


    LOGO

    Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. Board Voting Items Recommends 1. To elect each of the four nominees for director named in the accompanying proxy statement (the “proxy statement”) to hold office until the 2026 annual meeting of stockholders and until his successor is duly elected and qualified or, if sooner, until his earlier death, resignation or removal (“Proposal 1”); Nominees: For 01) Dale Curtis Hogue, Jr. 02) Robert W. Postma 03) Jaime Vieser 04) Holger Weis 2. To ratify the selection of Cherry Bekaert LLC as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025 by the audit committee of the board of directors of the Company For (the “Board”) (“Proposal 2”); 3. To approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the For proxy statement (“Proposal 3”); 4. To approve the amendment and restatement of the Company’s amended and restated certificate of incorporation, as amended (our “Charter”), in substantially the form attached to the proxy statement as Annex A, to, at the discretion of the Board, effect a reverse stock split with respect to the Company’s issued and outstanding common stock, par For value $0.001 per share, including stock held by the Company as treasury shares, at a reverse stock split ratio of 1-for-5 to 1-for-20, inclusive (“Proposal 4”); 5. To approve the Certificate of Amendment to the Company’s Charter, in substantially the form attached to the proxy statement as Annex B, to, at the discretion of the Board, increase the number of shares of common stock authorized For for issuance thereunder from 5,000,000 shares to 50,000,000 shares (“Proposal 5”); 6. To approve an amendment to the Company’s 2020 Equity Incentive Plan to increase the number of shares that the For Company may issue under the Plan from 130,745 shares to 1,130,745 shares (“Proposal 6”); and 7. To approve a proposal to adjourn the Annual Meeting to a later date, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the For approval of the Proposals in the proxy statement (“Proposal 7”). 8. To transact any other business as may properly come before the Annual Meeting or any adjournments thereof. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V75376-P34532

    Get the next $TCRT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TCRT

    DatePrice TargetRatingAnalyst
    10/4/2022$3.00Overweight
    Wells Fargo
    More analyst ratings

    $TCRT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Alaunos Therapeutics Inc.

      SC 13G/A - Alaunos Therapeutics, Inc. (0001107421) (Subject)

      11/14/24 4:06:27 PM ET
      $TCRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Alaunos Therapeutics Inc. (Amendment)

      SC 13G/A - Alaunos Therapeutics, Inc. (0001107421) (Subject)

      2/14/24 12:43:20 PM ET
      $TCRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Alaunos Therapeutics Inc. (Amendment)

      SC 13G/A - Alaunos Therapeutics, Inc. (0001107421) (Subject)

      2/13/24 4:58:29 PM ET
      $TCRT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TCRT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Postma Robert W was granted 20,804 shares, increasing direct ownership by 251% to 29,083 units (SEC Form 4)

      4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)

      4/15/25 8:42:09 PM ET
      $TCRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Weis Holger

      4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)

      4/15/25 8:33:33 PM ET
      $TCRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Vieser Jaime was granted 17,465 shares, increasing direct ownership by 67% to 43,359 units (SEC Form 4)

      4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)

      4/15/25 8:26:04 PM ET
      $TCRT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TCRT
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Alaunos Therapeutics Inc.

      DEFA14A - Alaunos Therapeutics, Inc. (0001107421) (Filer)

      5/21/25 8:45:49 AM ET
      $TCRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Alaunos Therapeutics Inc.

      DEF 14A - Alaunos Therapeutics, Inc. (0001107421) (Filer)

      5/21/25 8:42:50 AM ET
      $TCRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Alaunos Therapeutics Inc.

      10-Q - Alaunos Therapeutics, Inc. (0001107421) (Filer)

      5/15/25 4:27:18 PM ET
      $TCRT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TCRT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • PMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), To File Schedule 13D Reporting 5.09% Stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT)

      NEWPORT BEACH, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- PMGC Capital LLC ("PMGC Capital," "we," "our," or "us"), a wholly owned subsidiary of PMGC Holdings Inc. (NASDAQ:ELAB), today announced its planned filing of a Schedule 13D with the U.S. Securities and Exchange Commission disclosing beneficial ownership of common stock in Alaunos Therapeutics, Inc. (NASDAQ:TCRT). PMGC Capital has acquired 83,500 shares of Alaunos Therapeutics, representing approximately 5.09% of the company's outstanding shares of common stock, based on Alaunos' Preliminary Schedule 14A filed with the U.S. Securities and Exchange Commission, indicating 1,639,521 shares of common stock outstanding as of May 5, 2025.

      5/14/25 8:00:00 AM ET
      $ELAB
      $TCRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives

      TCR-T Library Phase 1/2 trial achieved an 87% disease control rate of eight evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all treated patientshunTR® discovered new HLA class I and class II restricted TCRs that recognize driver mutations, including KRAS and TP53Company continues to explore potential strategic alternatives; cost-savings measures expected to extend cash runaway into the second quarter of 2024 HOUSTON, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), today announced financial results for the third quarter ended September 30, 2023. As previously announced, the Compan

      11/14/23 7:30:00 AM ET
      $TCRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic Alternatives

      TCR-T Library Phase 1/2 trial achieved an 83% disease control rate of six evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all evaluable patientsCompany to wind down TCR-T Library Phase 1/2 trial and concurrently explore potential partnering opportunities for the hunTR® platform as well as broad strategic alternativesReducing headcount by approximately 60% while retaining key hunTR® R&D capabilities HOUSTON, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), today announced financial results for the second quarter ended June 30, 2023. The Company also announced a strategic repriori

      8/14/23 4:05:34 PM ET
      $TCRT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TCRT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wells Fargo resumed coverage on Alaunos Therapeutics with a new price target

      Wells Fargo resumed coverage of Alaunos Therapeutics with a rating of Overweight and set a new price target of $3.00

      10/4/22 7:18:05 AM ET
      $TCRT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TCRT
    Financials

    Live finance-specific insights

    See more

    $TCRT
    Leadership Updates

    Live Leadership Updates

    See more
    • Alaunos Therapeutics Reports First Quarter 2023 Financial Results

      Actively enrolling patients and manufacturing cryopreserved products for TCR-T Library Phase 1/2 trial; expect to report interim data in the third quarter of 2023Fully prepaid loan with Silicon Valley Bank; now a debt-free companyAmended exclusive licensing agreement with Precigen, Inc., reflecting the Company's focus on its TCR-T programs and eliminating long-term financial obligationsCompany to host conference call today at 9:00 a.m. ET HOUSTON, May 10, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announce

      5/10/23 7:00:17 AM ET
      $TCRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alaunos Therapeutics to Report First Quarter 2023 Financial Results on May 10, 2023

      HOUSTON, May 03, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that it will report financial results for the first quarter ended March 31, 2023, on Wednesday, May 10, 2023, before the open of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 9:00 a.m. ET to review the financial results and provide a corporate update. Register for the live webcast using the link here or by visiting the "Investors" section of the Alaunos website at www.alaunos.com. To partici

      5/3/23 8:30:00 AM ET
      $TCRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alaunos Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 7, 2023

      HOUSTON, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), a clinical-stage oncology-focused cell therapy company, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2022, on Tuesday, March 7, 2023, before the open of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:30 a.m. ET to review the financial results and provide a corporate update. Register for the live webcast using the link here or by visiting the "Investors" section of the Alaunos website at www.alaunos.com. To participate via telephone, please register in advance at

      2/28/23 4:01:07 PM ET
      $TCRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alaunos Therapeutics Appoints Dr. Robert J. Hofmeister to Board of Directors

      HOUSTON, March 30, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced the appointment of Robert J. Hofmeister, PhD, MS, Chief Scientific Officer of a stealth early stage biotechnology company, to the Company's Board of Directors, effective immediately. Dr. Hofmeister will replace Chris Bowden, MD. "We extend our gratitude to Chris for his invaluable contributions to Alaunos during his tenure, and welcome Robert to the Alaunos Board," said Kevin S. Boyle, Sr., Chief Executive Officer of Alaunos. "Robert bring

      3/30/23 7:00:40 AM ET
      $TCRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alaunos Therapeutics Appoints Abhishek Srivastava, Ph.D. as Vice President, Technical Operations

      HOUSTON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), a clinical-stage oncology-focused cell therapy company, today announced the appointment of Abhishek Srivastava, Ph.D. as Vice President of Technical Operations. Dr. Srivastava will lead the Company's manufacturing operations, including overseeing process optimization and capacity expansion. "Abhi brings extensive experience in cell therapy technical operations, and I am pleased to welcome him to our team," commented Kevin S. Boyle, Sr., Chief Executive Officer of Alaunos. "He joins Alaunos at an exciting time as we continue to advance development of our promising TCR T Library

      8/4/22 5:00:00 PM ET
      $TCRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CARsgen Appoints Dr. Raffaele Baffa as Chief Medical Officer

      SHANGHAI and BOSTON, April 7, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T cell therapies for the treatment of hematologic malignancies and solid tumors, announces that Dr. Raffaele Baffa ("Dr. Baffa") has been appointed as the Chief Medical Officer ("CMO") of the Company, responsible for overseeing the global clinical development strategies and operations for the Company's innovative pipeline product candidates. Dr. Baffa will report to Dr. Zonghai Li, Founder, Chairman of the Board, CEO, CSO of CARsgen Therapeutics Holdings Limited. Dr. Baffa has rich experiences in pharmaceutical industry and research institutes,

      4/7/22 11:42:00 AM ET
      $TCRT
      $ZIOP
      Biotechnology: Pharmaceutical Preparations
      Health Care